Cite
Association Between Claims-Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study.
MLA
Faridi, Kamil F., et al. “Association Between Claims-Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study.” Journal of the American Heart Association, vol. 12, no. 14, July 2023, p. e029588. EBSCOhost, https://doi.org/10.1161/JAHA.123.029588.
APA
Faridi, K. F., Strom, J. B., Kundi, H., Butala, N. M., Curtis, J. P., Gao, Q., Song, Y., Zheng, L., Tamez, H., Shen, C., Secemsky, E. A., & Yeh, R. W. (2023). Association Between Claims-Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study. Journal of the American Heart Association, 12(14), e029588. https://doi.org/10.1161/JAHA.123.029588
Chicago
Faridi, Kamil F, Jordan B Strom, Harun Kundi, Neel M Butala, Jeptha P Curtis, Qi Gao, Yang Song, et al. 2023. “Association Between Claims-Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study.” Journal of the American Heart Association 12 (14): e029588. doi:10.1161/JAHA.123.029588.